IP Library › Assignment 058463/0187
Patent Assignment
Reel/Frame 058463/0187

Security Interest

Recorded: 2021-12-22 Pages: 19
Assignor
ARCUTIS BIOTHERAPEUTICS, INC.
Executed: 2021-12-22
Assignee
SLR INVESTMENT CORP., AS AGENT
500 PARK AVENUE, 3RD FLOOR, NEW YORK, NEW YORK, 10022
Covered Properties (32)
Pharmaceutical Compositions of Roflumilast in Aqueous Blends of Water-Miscible, Pharmaceutically Acceptable Solvents
Application: 15/712,900 →
Publication: US 2019/0091333
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
Application: 62/742,644 →
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
Application: 16/426,492 →
Publication: US 2019/0365642
Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitors
Application: 62/768,314 →
Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitors
Application: 16/563,435 →
Publication: US 2020/0155524
Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitors
Application: 17/327,236 →
Publication: US 2021/0275509
Topical Roflumilast Formulation Having Improved Delivery and Plasma Half Life
Application: 17/402,051 →
Publication: US 2021/0386719
Roflumilast Formulations with an Improved Pharmacokinetic Profile
Application: 17/155,679 →
Publication: US 2021/0161870
Inhibition of Crystal Growth of Roflumilast
Application: 17/102,056 →
Publication: US 2021/0244718
Treatment of Skin Conditions Using High Krafft Temperature Anionic Surfactants
Application: 63/021,400 →
Laureth-4 Containing Topical Formulations
Application: 63/057,503 →
Laureth-4 Containing Topical Formulations
Application: 17/443,699 →
Publication: US 2022/0031705
Methods for Treating Vitiligo Lesions Having Improved Efficacy
Application: 63/106,983 →
Methods for Treating Vitiligo Lesions Having Improved Efficacy
Application: 17/513,199 →
Publication: US 2022/0133728
Compositions and Methods for Deep Dermal Drug Delivery
Application: 63/114,887 →
Compositions and Methods for Deep Dermal Drug Delivery
Application: 63/221,349 →
Compositions and Methods for Deep Dermal Drug Delivery
Application: 17/527,688 →
Publication: US 2022/0152033
Compositions and Methods for Deep Dermal Drug Delivery
Application: 17/527,856 →
Publication: US 2022/0152061
Inhibition of Crystal Growth of Roflumilast
Patent: 9,895,359 →
Application: 15/616,409 →
Inhibition of Crystal Growth of Roflumilast
Patent: 9,884,050 →
Application: 15/676,356 →
Inhibition of Crystal Growth of Roflumilast
Patent: 9,907,788 →
Application: 15/676,373 →
Inhibition of Crystal Growth of Roflumilast
Application: 15/848,505 →
Inhibition of Crystal Growth of Roflumilast
Application: 15/848,462 →
Publication: US 2018/0353490
Inhibition of Crystal Growth of Roflumilast
Application: 16/136,804 →
Publication: US 2019/0015398
Topical Roflumilast Formulation Having Improved Delivery and Plasma Half Life
Application: 16/778,845 →
Publication: US 2020/0163944
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitors
Treatment of Skin Conditions Using High Krafft Temperature Anionic Surfactants
Laureth-4 Containing Topical Formulations
Methods for Treating Vitiligo Lesions Having Improved Efficacy
Compositions and Methods for Deep Dermal Drug Delivery
Compositions and Methods for Deep Dermal Drug Delivery
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jun 7, 2017
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 042638/0206 →
Assignment of Assignor's Interest Sep 22, 2017
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 043666/0232 →
Assignment of Assignor's Interest May 2, 2019
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 049063/0275 →
Assignment of Assignor's Interest May 3, 2019
From: WELGUS, HOWARD; THURSTON, ARCHIE W., JR; OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 049085/0209 →
Corrective Assignment to Correct the Name of the City Previously Recorded on Reel 049063 Frame 0275. Assignor(S) Hereby Confirms the Assignment. May 30, 2019
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 049318/0210 →
Assignment of Assignor's Interest Aug 28, 2020
From: OSBORNE, DAVID W.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 053627/0481 →
Assignment of Assignor's Interest Oct 29, 2020
From: HIGHAM, ROBERT; BERK, DAVID; WATANABE, FRANK
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 054210/0886 →
Assignment of Assignor's Interest Nov 17, 2020
From: OSBORNE, DAVID W.; TOFIG, BABAK N.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 054394/0660 →
Assignment of Assignor's Interest Jan 22, 2021
From: WELGUS, HOWARD; THURSTON, ARCHIE W.; OSBORNE, DAVID W.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 055002/0821 →
Assignment of Assignor's Interest Jul 19, 2021
From: OSBORNE, DAVID W.; TOFIG, BABAK N.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 056902/0001 →
Assignment of Assignor's Interest Aug 12, 2021
From: OSBORNE, DAVID W.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 057164/0456 →
Change of Name Aug 31, 2021
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 057394/0812 →
Assignment of Assignor's Interest Nov 3, 2021
From: HIGHAM, ROBERT; BERK, DAVID; WATANABE, FRANK
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 058010/0222 →
Assignment of Assignor's Interest Apr 4, 2022
From: OSBORNE, DAVID W.; TOFIG, BABAK N.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 059491/0222 →
Assignment of Assignor's Interest Apr 4, 2022
From: OSBORNE, DAVID W.; TOFIG, BABAK N.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 059492/0836 →
Change of Name Nov 16, 2022
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 061951/0886 →
Assignment of Assignor's Interest Aug 9, 2023
From: OSBORNE, DAVID
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 064539/0360 →
Change of Name Dec 22, 2023
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 066122/0472 →
Assignment of Assignor's Interest Feb 26, 2024
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 066560/0442 →
Assignment of Assignor's Interest Feb 28, 2024
From: OSBORNE, DAVID W., DR.
To: ARCUTIS, INC.
Reel/Frame 066592/0898 →
Assignment of Assignor's Interest Feb 28, 2024
From: OSBORNE, DAVID W, DR.
To: ARCUTIS, INC.
Reel/Frame 066592/0237 →
Assignment of Assignor's Interest Mar 6, 2024
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 066662/0184 →
Change of Name Mar 6, 2024
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 066742/0412 →
Change of Name Mar 19, 2024
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 066821/0809 →
Assignment of Assignor's Interest Mar 19, 2024
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 066821/0437 →